Evaxion A/S Files Routine 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-07-02T00:00:00.000Z

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

TL;DR

Evaxion A/S filed a standard 6-K, no major news.

AI Summary

Evaxion A/S filed a Form 6-K on July 2, 2025, for the month of July 2025. The company, previously known as Evaxion Biotech A/S, is a foreign private issuer based in Hoersholm, Denmark. This filing is routine and does not appear to contain specific financial updates or material events.

Why It Matters

This filing indicates Evaxion A/S is fulfilling its reporting obligations as a foreign private issuer, which is standard practice for companies listed on US exchanges.

Risk Assessment

Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.

When was Evaxion A/S previously known by another name?

Evaxion A/S was formerly known as Evaxion Biotech A/S, with a date of name change on October 14, 2020.

Where is Evaxion A/S's principal executive office located?

Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does Evaxion A/S file annual reports under Form 20-F?

Yes, Evaxion A/S indicates it files annual reports under cover of Form 20-F.

What is the SIC code for Evaxion A/S?

The Standard Industrial Classification (SIC) code for Evaxion A/S is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0001171843-25-004265.txt : 20250702 0001171843-25-004265.hdr.sgml : 20250702 20250702060025 ACCESSION NUMBER: 0001171843-25-004265 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250701 FILED AS OF DATE: 20250702 DATE AS OF CHANGE: 20250702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251098255 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_070125.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S's (the "Company") registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Executive Management Changes In a Press Release dated July 1, 2025, Evaxion A/S (the “Company”), announced certain executive management changes. The Company announced that Christian Kanstrup has resigned as the Company’s Chief Executive Officer (“CEO”).  Dr. Birgitte Rønø, Evaxion’s Chief Scientific Officer, has been appointed interim CEO. Dr. Rønø has been with the Company since 2018 and brings deep scientific and strategic expertise to the role. The Company also annou

View on Read The Filing